Targeted treatments for the EWS‑ATF1 change in clear cell sarcoma
Targeting EWS-ATF1 Fusion in Clear Cell Sarcoma of Soft Tissue
['FUNDING_R01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11231267
Researchers are developing new targeted treatments aimed at the EWS‑ATF1 fusion for people with clear cell sarcoma, especially those whose cancer has spread or doesn't respond to standard chemotherapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11231267 on ClinicalTrials.gov |
What this research studies
This project focuses on clear cell sarcoma, a rare and aggressive cancer often driven by the EWS‑ATF1 fusion gene. The team will design and test drugs that block the abnormal EWS‑ATF1 protein using laboratory tumor cells and animal models, and will analyze tumor tissue from patients to see how the drugs work. They plan to identify compounds that stop tumor growth and to map the pathways that make this cancer resistant to existing chemotherapy. If promising candidates are found, the work is intended to move toward early human testing.
Who could benefit from this research
Good fit: People diagnosed with clear cell sarcoma of soft tissue, especially adolescents and young adults whose tumors carry the EWS‑ATF1 fusion or who have metastatic or chemotherapy-resistant disease, would be the most relevant candidates.
Not a fit: Patients with other types of sarcoma or without the EWS‑ATF1 fusion are unlikely to benefit from these targeted approaches.
Why it matters
Potential benefit: If successful, the work could produce the first effective targeted systemic treatments for metastatic clear cell sarcoma and improve survival and limb-sparing options.
How similar studies have performed: Approaches that target fusion oncoproteins have succeeded in other cancers, but direct therapies for EWS‑ATF1 in clear cell sarcoma are largely new and remain unproven.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, BINGBING — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: LI, BINGBING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.